We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMCR icon
26
Immunocore
IMCR
$1.86B
$8.09M 1.02%
254,863
+61,674
+32% +$1.82M
CAPR icon
27
CALL
Capricor Therapeutics
CAPR
$547M
$7.93M 1%
329,300
– –
NVS icon
28
CALL
Novartis
NVS
$304B
$7.84M 0.99%
+50,000
New +$7.5M
REPL icon
29
CALL
Replimune Group
REPL
$1.42B
$7.71M 0.97%
696,300
+490,800
+239% +$3M
KOD icon
30
CALL
Kodiak Sciences
KOD
$2.22B
$7.66M 0.97%
196,700
+196,500
+98,250% +$7.65M
FDMT icon
31
4D Molecular Therapeutics
FDMT
$827M
$7.6M 0.96%
+571,107
New +$5.56M
MRNA icon
32
PUT
Moderna
MRNA
$58.1B
$7M 0.88%
100,000
-59,400
-37% -$3.07M
HIMS icon
33
CALL
Hims & Hers Health
HIMS
$6.47B
$6.93M 0.88%
+200,000
New +$5.37M
RCUS icon
34
Arcus Biosciences
RCUS
$3.78B
$6.9M 0.87%
223,810
-14,332
-6% -$354K
HIMS icon
35
PUT
Hims & Hers Health
HIMS
$6.47B
$6.72M 0.85%
+193,700
New +$5.2M
CRBP icon
36
CALL
Corbus Pharmaceuticals
CRBP
$214M
$5.95M 0.75%
633,800
+518,500
+450% +$4.91M
SLS icon
37
CALL
SELLAS Life Sciences
SLS
$2.8B
$5.9M 0.75%
400,000
+100,000
+33% +$690K
KOD icon
38
PUT
Kodiak Sciences
KOD
$2.22B
$5.72M 0.72%
146,900
-100,000
-41% -$3.89M
ALMS
39
CALL
Alumis Inc
ALMS
$1.44B
$5.63M 0.71%
200,000
+100,000
+100% +$2.33M
RPRX icon
40
CALL
Royalty Pharma
RPRX
$28.5B
$5.61M 0.71%
+100,000
New +$5.2M
JNJ icon
41
Johnson & Johnson
JNJ
$663B
$5.59M 0.71%
22,000
-31,771
-59% -$7.4M
REPL icon
42
PUT
Replimune Group
REPL
$1.42B
$5.56M 0.7%
502,500
+42,600
+9% +$261K
BIOA
43
CALL
BioAge Labs
BIOA
$440M
$4.9M 0.62%
+200,100
New +$3.62M
NVO
44
Novo Nordisk
NVO
$206B
$4.81M 0.61%
100,000
+85,423
+586% +$3.67M
BHVN icon
45
CALL
Biohaven
BHVN
$2.37B
$4.72M 0.6%
317,000
– –
TENX icon
46
CALL
Tenax Therapeutics
TENX
$72.6M
$4.47M 0.56%
+307,000
New +$3.92M
CRVS icon
47
Corvus Pharmaceuticals
CRVS
$1.21B
$4.4M 0.56%
294,811
+50,000
+20% +$694K
RLAY icon
48
Relay Therapeutics
RLAY
$4.17B
$4.32M 0.55%
+230,677
New +$3.35M
TGTX icon
49
CALL
TG Therapeutics
TGTX
$8.57B
$4.16M 0.53%
+75,700
New +$3.1M
GLUE icon
50
CALL
Monte Rosa Therapeutics
GLUE
$1.18B
$4.12M 0.52%
+170,100
New +$3.21M
1
2
3 4 5

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.